Leukaemic relapse of anaplastic large cell lymphoma, ALK negative

Nabin Raj Karki, Kristine Badin, Natasha Savage, Locke Bryan

Research output: Contribution to journalArticlepeer-review

Abstract

Anaplastic large cell lymphoma (ALCL), ALK negative (ALK-) is an aggressive lymphoproliferative disorder of mature T lymphocytes characterised by hallmark cells, CD30 positivity and lacking ALK protein expression. ALCL, ALK-has to be differentiated from peripheral T-cell lymphoma-not otherwise specified and classical Hodgkin's lymphoma. ALK-anaplastic large cell leukaemia should be considered in a patient with a history of ALCL, ALK-presenting with new leukaemia. We report a rare presentation of relapsed ALCL, ALK-with leukaemia after autologous stem cell transplantation in a 57-year-old male. Leukaemia, either as primary presentation or secondary transformation confers worse prognosis in ALCL, ALK-with very few cases reported so far. Emergency resuscitation with leukapheresis and treatment of tumour lysis syndrome along with supportive care should be followed by combination chemotherapy. Brentuximab vedotin and stem cell transplantation are the backbone of treatment for relapsed/refractory disease.

Original languageEnglish (US)
Article numbere239213
JournalBMJ Case Reports
Volume14
Issue number2
DOIs
StatePublished - Feb 22 2021

Keywords

  • haematology (incl blood transfusion)
  • oncology
  • screening (oncology)

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Leukaemic relapse of anaplastic large cell lymphoma, ALK negative'. Together they form a unique fingerprint.

Cite this